var data={"title":"Treatment of pulmonary tuberculosis in HIV-infected adults: Follow-up after initiation of therapy","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment of pulmonary tuberculosis in HIV-infected adults: Follow-up after initiation of therapy</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/contributors\" class=\"contributor contributor_credentials\">Timothy R Sterling, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/contributors\" class=\"contributor contributor_credentials\">C Fordham von Reyn, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 09, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The approach to monitoring the human immunodeficiency virus (HIV)-infected patient on antituberculous medications must include consideration of the antituberculous regimen, the antiretroviral therapy regimen, potential drug reactions, and complications related to the immune reconstitution inflammatory syndrome (IRIS).</p><p>This topic will cover the issues related to monitoring of HIV-infected patients with tuberculosis (TB), including directly observed therapy, the clinical response to treatment, adverse events related to treatment, duration of treatment, and prognosis.</p><p>Issues related to clinical manifestations, diagnosis, and treatment of susceptible TB in HIV-infected patients are discussed elsewhere. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy&quot;</a> and <a href=\"topic.htm?path=diagnosis-of-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">&quot;Diagnosis of pulmonary tuberculosis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2274974346\"><span class=\"h1\">INITIATION OF THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Issues related to selection of antituberculous therapy and antiretroviral therapy are discussed separately. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1758484531\"><span class=\"h1\">DURATION OF THERAPY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The standard duration of therapy for treatment of drug-susceptible pulmonary TB in HIV-infected patients on antiretroviral therapy (ART) is six months. This includes an intensive phase of four drugs (<a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, a rifamycin [eg, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> or <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>], <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, and <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>) administered for two months, followed by a continuation phase of two drugs (isoniazid and a rifamycin) administered for four months [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/1,2\" class=\"abstract_t\">1,2</a>].</p><p>All HIV-infected patients should be started on ART during treatment of tuberculosis. Issues related to timing of therapy are discussed separately. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy#H1059142102\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy&quot;, section on 'Timing'</a>.)</p><p>In rare instances in which ART is not administered during antituberculous therapy (ie, if ART is not available or if there are unavoidable concerns regarding drug interactions), the continuation phase of antituberculous therapy should be extended for an additional three months (ie, a continuation phase of seven months, corresponding to a total of nine months of antituberculous therapy) [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Further study is needed to address the optimal duration of antituberculous therapy in HIV-infected patients. In a 2012 meta-analysis including 6 randomized trials and 21 cohort studies, relapse was more common among patients whose regimens included two months of rifamycin than among patients whose regimens included at least eight months of rifamycin (adjusted risk ratio 5.0, 95% CI 1.9-13.2). The risk of relapse was lower with <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> treatment for &ge;9 months compared with 6 months of rifampin (pooled risk difference -9.1 percent, 95% CI -16.5 to -1.8 percent) [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/3,4\" class=\"abstract_t\">3,4</a>]. However, available antiretroviral therapy has improved substantially since this study was performed [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>].</p><p>For those patients with cavitary disease and positive sputum cultures after two months of treatment, the duration of the continuation phase should be extended from four to seven months (total duration of treatment extended from six to nine months) [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/1,2\" class=\"abstract_t\">1,2</a>]. No further adjustments in duration of therapy are warranted for patients who did not receive ART during antituberculous therapy (ie, total duration of antituberculous therapy nine months).</p><p>Issues related to duration of therapy for HIV-infected patients with drug-resistant TB are discussed separately. (See <a href=\"topic.htm?path=treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">&quot;Treatment of drug-resistant pulmonary tuberculosis in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3288296675\"><span class=\"h1\">CLINICAL MONITORING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HIV-infected patients with TB generally respond well to therapy if the diagnosis is made promptly and standard therapy instituted. Fever usually resolves within one month; improvement in chest radiograph findings may take longer.</p><p class=\"headingAnchor\" id=\"H856245311\"><span class=\"h2\">Sputum monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During treatment of pulmonary tuberculosis, sputum should be obtained for acid-fast bacilli (AFB) smear and culture at monthly intervals until two consecutive cultures are negative [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>]. Sputum AFB smear and culture at the end of the intensive phase (after two months of treatment) is particularly important for assessing relapse risk and for determining the duration of the continuation phase (<a href=\"image.htm?imageKey=ID%2F109259\" class=\"graphic graphic_algorithm graphicRef109259 \">algorithm 1</a>).</p><p>The approach in the setting of persistently positive sputum culture is discussed below. (See <a href=\"#H2748843968\" class=\"local\">'Persistently positive sputum culture'</a> below.)</p><p>After the sputum smear has converted to negative, at least one sputum should be collected at the completion of therapy to confirm that the patient has remained smear and culture negative [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H2848278702\"><span class=\"h2\">Drug-related side effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Antituberculous drugs are associated with a broad array of adverse effects, and the likelihood of adverse effects may be increased in HIV-infected patients [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/5\" class=\"abstract_t\">5</a>].</p><p>Patient education regarding symptoms of hepatitis and other possible drug toxicities should be reinforced at each return visit, at least monthly. Patients should be instructed to report signs or symptoms of toxicity immediately and stop antituberculous medications until advised to resume treatment.</p><p>Issues related to adverse effects associated with antituberculous drugs are discussed separately. (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H464788134\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Adverse effects'</a>.)</p><p>Issues related to laboratory monitoring for patients on antituberculous drugs are discussed separately. (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H2636671244\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Clinical and laboratory monitoring for adverse effects'</a>.)</p><p>It may be beneficial to check liver function tests after two weeks of antituberculous therapy for early detection of toxicity [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/6\" class=\"abstract_t\">6</a>]. Thereafter, HIV-infected patients who warrant serial liver function test monitoring may be followed monthly.</p><p>Issues related to regimen adjustment for drug intolerance and management of hepatotoxicity associated with antituberculous therapy are discussed separately. (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults#H9\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;, section on 'Regimen adjustments for drug intolerance'</a>.)</p><p><a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">Isoniazid</a> is associated with peripheral neuropathy; the risk is increased in patients taking concomitant <a href=\"topic.htm?path=stavudine-drug-information\" class=\"drug drug_general\">stavudine</a> (which is associated with mitochondrial toxicity). Development of peripheral neuropathy should prompt discontinuation of stavudine with adjustment of the ART regimen accordingly [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/7\" class=\"abstract_t\">7</a>].</p><p class=\"headingAnchor\" id=\"H1868326374\"><span class=\"h2\">Therapeutic drug monitoring</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Therapeutic drug monitoring need not be performed routinely. Drug concentrations may be useful for patients with slow response to therapy (eg, positive sputum smear or culture after two months of therapy) <span class=\"nowrap\">and/or</span> possibility of drug-drug interactions [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/8-10\" class=\"abstract_t\">8-10</a>]. Issues related to drug monitoring are discussed further separately. (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H1618032856\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Serum drug concentration monitoring'</a>.)</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">PATIENTS WITH INADEQUATE CLINICAL RESPONSE</span></p><p class=\"headingAnchor\" id=\"H3793220151\"><span class=\"h2\">General principles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Inadequate clinical response or clinical deterioration in an HIV-infected patient with TB may be attributable to poor adherence, poor drug absorption, emergence of drug resistance, an intercurrent opportunistic infection, or the immune reconstitution inflammatory syndrome (IRIS).</p><p>The approach to distinguishing between causes of inadequate clinical response depends in part on the timing relative to initiation of antituberculous therapy:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug hypersensitivity (usually manifesting as rash or systemic reactions) generally occurs in the first few weeks of therapy.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>IRIS usually occurs approximately three weeks after starting ART, though it can occur later. (See <a href=\"#H11\" class=\"local\">'Immune reconstitution inflammatory syndrome'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment failure is defined as positive sputum culture after four to five months of treatment. Persistently positive sputum culture may be attributable to poor adherence, poor drug absorption, <span class=\"nowrap\">and/or</span> emergence of drug resistance. (See <a href=\"#H2748843968\" class=\"local\">'Persistently positive sputum culture'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Relapse is defined as recurrent signs and symptoms after successful completion of treatment.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intercurrent opportunistic infection is possible at any time point so must be included routinely in the differential diagnosis and clinical evaluation. (See <a href=\"#H10\" class=\"local\">'Intercurrent opportunistic infection'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H2748843968\"><span class=\"h2\">Persistently positive sputum culture</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The approach to sputum monitoring is described above. (See <a href=\"#H856245311\" class=\"local\">'Sputum monitoring'</a> above.)</p><p>Persistently positive sputum culture may be attributable to poor adherence, poor drug absorption, <span class=\"nowrap\">and/or</span> emergence of drug resistance:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Adherence should be reviewed; directly observed therapy (DOT) should be implemented if this has not already been done. (See <a href=\"topic.htm?path=adherence-to-tuberculosis-treatment\" class=\"medical medical_review\">&quot;Adherence to tuberculosis treatment&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Therapeutic drug monitoring should be pursued since poor drug absorption is common among HIV-infected patients. This is particularly true in the setting of diarrhea <span class=\"nowrap\">and/or</span> malabsorption but may occur even in the absence of these symptoms [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/11-14\" class=\"abstract_t\">11-14</a>]. Issues related to drug monitoring are discussed further separately. (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H1618032856\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Serum drug concentration monitoring'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug susceptibility testing on a current isolate should be pursued [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/2\" class=\"abstract_t\">2</a>]. Patients with drug-resistant isolates should be treated as discussed separately. (See <a href=\"topic.htm?path=treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">&quot;Treatment of drug-resistant pulmonary tuberculosis in adults&quot;</a>.) </p><p/><p class=\"headingAnchor\" id=\"H1971166980\"><span class=\"h2\">Persistent symptoms and/or radiographic findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Persistent symptoms <span class=\"nowrap\">and/or</span> radiographic findings may be attributable to an intercurrent opportunistic infection, IRIS, <span class=\"nowrap\">and/or</span> the causes of persistently positive sputum discussed in the preceding section (eg, poor adherence, poor drug absorption, <span class=\"nowrap\">and/or</span> emergence of drug resistance).</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Intercurrent opportunistic infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>New clinical findings such as fever, cough, or weight loss or new radiographic abnormalities (in an HIV-infected patient on appropriate TB therapy whose sputum smear becomes negative) suggest the development of an intercurrent opportunistic infection [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/5\" class=\"abstract_t\">5</a>]. Diagnostic considerations include <em>Pneumocystis jirovecii</em> pneumonia (PJP), pneumonia due to other bacterial, viral, or fungal causes, and lymphoma. (See <a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-pneumocystis-pulmonary-infection-in-hiv-infected-patients\" class=\"medical medical_review\">&quot;Clinical presentation and diagnosis of Pneumocystis pulmonary infection in HIV-infected patients&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h3\">Immune reconstitution inflammatory syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical <span class=\"nowrap\">and/or</span> radiographic deterioration despite appropriate antituberculous chemotherapy may reflect IRIS, a paradoxical worsening of a preexisting infectious process following immune recovery associated with administration of antiretroviral therapy [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/15-20\" class=\"abstract_t\">15-20</a>]. IRIS usually occurs approximately three weeks after starting ART, though it can occur later. Issues related to timing of ART to minimize IRIS are discussed separately. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy#H1059142102\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy&quot;, section on 'Timing'</a>.)</p><p>Among patients with TB, IRIS has been described in 8 to 43 percent of cases [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/15,17,21,22\" class=\"abstract_t\">15,17,21,22</a>]. The risk is increased in patients with an initial CD4 count below <span class=\"nowrap\">100/microL</span> [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/21\" class=\"abstract_t\">21</a>] and in patients with a significant reduction in viral load and a larger increase in CD4 count [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/22\" class=\"abstract_t\">22</a>].</p><p>Clinical manifestations of IRIS in the HIV-infected patient with TB include new or expanding lymph nodes or abscesses, enlarging intracranial tuberculomas, persistent pyrexia, worsening pulmonary infiltrates, and new serositis [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/19\" class=\"abstract_t\">19</a>]. Management of TB-IRIS does not differ substantially from management of IRIS associated with other conditions. (See <a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome#H743844635\" class=\"medical medical_review\">&quot;Immune reconstitution inflammatory syndrome&quot;, section on 'Tuberculosis'</a>.)</p><p>IRIS is usually self-limited and in general does not require alteration or interruption of the antituberculous or antiretroviral regimens. Administration of nonsteroidal anti-inflammatory drugs or a short course of corticosteroids is warranted for IRIS causing significant symptoms [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/1\" class=\"abstract_t\">1</a>]. Treatment should be undertaken only after a thorough evaluation to exclude other potential causes of clinical deterioration.</p><p>For management of symptomatic involvement such as impingement of the airway or major vessel (eg, vena cava) by enlarged mediastinal lymph nodes, use of corticosteroids (<a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 1 <span class=\"nowrap\">mg/kg</span> orally per day) is reasonable. The dose should be tapered as symptoms allow; worsening of symptoms with tapering should prompt reversion to a higher dose.</p><p class=\"headingAnchor\" id=\"H25\"><span class=\"h1\">OUTCOMES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with HIV infection and drug-sensitive tuberculosis generally respond well to therapy if the diagnosis is made promptly and standard therapy instituted. Fever usually resolves within one month and the chest radiograph typically improves at two to three months [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/5,23,24\" class=\"abstract_t\">5,23,24</a>]. In a series published prior to the antiretroviral therapy (ART) era including 82 HIV-infected patients with drug-susceptible TB, treatment failure occurred in only 5 percent of cases; all failures were attributable to poor adherence [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/25\" class=\"abstract_t\">25</a>].</p><p>Treatment for drug-susceptible TB in HIV-infected patients is associated with rates of culture conversion and completion of therapy comparable to rates in HIV-uninfected patients [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/2,26\" class=\"abstract_t\">2,26</a>]. This was illustrated in an observational study of 280 patients with TB; patients whose HIV status was positive, negative, and unknown had relapse rates of 6.0, 5.5, and 3.0 percent, respectively [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/27\" class=\"abstract_t\">27</a>].</p><p>ART has significantly decreased mortality related to TB; this is most evident in resource-limited settings where TB is endemic. In a prospective study in Thailand including 290 HIV-infected patients with TB, survival was more likely among patients who received ART than those who did not (7 versus 43 percent) [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/28\" class=\"abstract_t\">28</a>].</p><p>Treatment for HIV infection appears to be as effective in the <span class=\"nowrap\">HIV/TB</span> coinfected patients as in patients with HIV alone. This was illustrated in an observational study including 111 HIV-infected patients with TB and 45 HIV-infected patients without concomitant TB (matched for gender, ethnicity, and baseline CD4 cell count) [<a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/29\" class=\"abstract_t\">29</a>]. Viral suppression was achieved at six months in similar proportions of <span class=\"nowrap\">HIV/TB-coinfected</span> patients and patients with HIV alone (87 versus 88 percent). Similar improvements in CD4 cell counts were also noted between <span class=\"nowrap\">HIV/TB-coinfected</span> patients and HIV-infected controls (97 versus 89 <span class=\"nowrap\">cells/microL)</span>. Most patients in the study were taking a nonnucleoside reverse transcriptase inhibitor along with two nucleoside analogs.</p><p class=\"headingAnchor\" id=\"H3454422568\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Opportunistic infections in HIV-infected adults and adolescents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H29\"><span class=\"h1\">SUMMARY</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The approach to monitoring the human immunodeficiency virus (HIV)-infected patient with pulmonary tuberculosis (TB) on antituberculous medications must include consideration of the antituberculous regimen, the antiretroviral therapy (ART) regimen, potential drug reactions, and complications related to the immune reconstitution inflammatory syndrome (IRIS). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Issues related to selection of antituberculous therapy and antiretroviral therapy are discussed separately. (See <a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">&quot;Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The standard duration of therapy for treatment of drug-susceptible pulmonary TB in HIV-infected patients on ART is six months. This includes an intensive phase of four drugs (<a href=\"topic.htm?path=isoniazid-drug-information\" class=\"drug drug_general\">isoniazid</a>, a rifamycin [eg, <a href=\"topic.htm?path=rifampin-rifampicin-drug-information\" class=\"drug drug_general\">rifampin</a> or <a href=\"topic.htm?path=rifabutin-drug-information\" class=\"drug drug_general\">rifabutin</a>], <a href=\"topic.htm?path=pyrazinamide-drug-information\" class=\"drug drug_general\">pyrazinamide</a>, and <a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">ethambutol</a>) administered for two months, followed by a continuation phase of two drugs (isoniazid and a rifamycin) administered for four months. (See <a href=\"#H1758484531\" class=\"local\">'Duration of therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In rare instances in which ART is not administered during antituberculous therapy (ie, ART is not available or there are unavoidable concerns regarding drug interactions), the continuation phase should be extended for an additional three months (ie, a continuation phase of seven months), corresponding to a total of nine months of antituberculous therapy. (See <a href=\"#H1758484531\" class=\"local\">'Duration of therapy'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>During treatment of pulmonary TB, sputum should be obtained for acid-fast bacilli (AFB) smear and culture at monthly intervals until two consecutive cultures are negative. Sputum AFB smear and culture at the end of the intensive phase (after two months of treatment) is particularly important for assessing relapse risk and for determining the duration of the continuation phase (<a href=\"image.htm?imageKey=ID%2F109259\" class=\"graphic graphic_algorithm graphicRef109259 \">algorithm 1</a>). (See <a href=\"#H856245311\" class=\"local\">'Sputum monitoring'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patient education regarding symptoms of hepatitis and other possible drug toxicities should be reinforced at each follow-up visit, at least monthly. Patients should be instructed to report signs or symptoms of toxicity immediately and stop antituberculous medications until advised to resume. (See <a href=\"#H2848278702\" class=\"local\">'Drug-related side effects'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Issues related to adverse effects and laboratory monitoring for patients on antituberculous drugs are discussed separately. (See <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H464788134\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Adverse effects'</a> and <a href=\"topic.htm?path=antituberculous-drugs-an-overview#H2636671244\" class=\"medical medical_review\">&quot;Antituberculous drugs: An overview&quot;, section on 'Clinical and laboratory monitoring for adverse effects'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Issues related to regimen adjustment for drug intolerance and management of hepatotoxicity associated with antituberculous therapy are discussed separately. (See <a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults#H9\" class=\"medical medical_review\">&quot;Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults&quot;, section on 'Regimen adjustments for drug intolerance'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Inadequate clinical response or clinical deterioration in an HIV-infected patient with TB may be attributable to poor adherence, poor drug absorption, emergence of drug resistance, an intercurrent opportunistic infection, or the immune reconstitution inflammatory syndrome. (See <a href=\"#H7\" class=\"local\">'Patients with inadequate clinical response'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li class=\"breakAll\">Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on January 19, 2016).</li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/2\" class=\"nounderline abstract_t\">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/3\" class=\"nounderline abstract_t\">Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50:1288.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/4\" class=\"nounderline abstract_t\">Ahmad Khan F, Minion J, Al-Motairi A, et al. An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection. Clin Infect Dis 2012; 55:1154.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/5\" class=\"nounderline abstract_t\">Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300:423.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/6\" class=\"nounderline abstract_t\">Singanayagam A, Sridhar S, Dhariwal J, et al. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med 2012; 185:653.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/7\" class=\"nounderline abstract_t\">Cohen K, Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS 2010; 5:61.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/8\" class=\"nounderline abstract_t\">Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014; 74:839.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/9\" class=\"nounderline abstract_t\">Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48:1685.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/10\" class=\"nounderline abstract_t\">Pasipanodya JG, McIlleron H, Burger A, et al. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 2013; 208:1464.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/11\" class=\"nounderline abstract_t\">Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996; 30:919.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/12\" class=\"nounderline abstract_t\">Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997; 127:289.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/13\" class=\"nounderline abstract_t\">Perlman DC, Segal Y, Rosenkranz S, et al. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis 2005; 41:1638.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/14\" class=\"nounderline abstract_t\">Peloquin CA. Therapeutic drug monitoring of the antimycobacterial drugs. Clin Lab Med 1996; 16:717.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/15\" class=\"nounderline abstract_t\">Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158:157.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/16\" class=\"nounderline abstract_t\">Fishman JE, Saraf-Lavi E, Narita M, et al. Pulmonary tuberculosis in AIDS patients: transient chest radiographic worsening after initiation of antiretroviral therapy. AJR Am J Roentgenol 2000; 174:43.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/17\" class=\"nounderline abstract_t\">Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008; 8:516.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/18\" class=\"nounderline abstract_t\">Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT trial. Ann Intern Med 2012; 157:313.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/19\" class=\"nounderline abstract_t\">Breton G, Duval X, Estellat C, et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 2004; 39:1709.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/20\" class=\"nounderline abstract_t\">Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/21\" class=\"nounderline abstract_t\">Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190:1670.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/22\" class=\"nounderline abstract_t\">Navas E, Mart&iacute;n-D&aacute;vila P, Moreno L, et al. Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 2002; 162:97.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/23\" class=\"nounderline abstract_t\">Hopewell PC. Impact of human immunodeficiency virus infection on the epidemiology, clinical features, management, and control of tuberculosis. Clin Infect Dis 1992; 15:540.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/24\" class=\"nounderline abstract_t\">Horsburgh CR Jr, Barry CE 3rd, Lange C. Treatment of Tuberculosis. N Engl J Med 2015; 373:2149.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/25\" class=\"nounderline abstract_t\">Jones BE, Otaya M, Antoniskis D, et al. A prospective evaluation of antituberculosis therapy in patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1994; 150:1499.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/26\" class=\"nounderline abstract_t\">Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159:733.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/27\" class=\"nounderline abstract_t\">Sterling TR, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. AIDS 1999; 13:1899.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/28\" class=\"nounderline abstract_t\">Akksilp S, Karnkawinpong O, Wattanaamornkiat W, et al. Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. Emerg Infect Dis 2007; 13:1001.</a></li><li><a href=\"https://www.uptodate.com/contents/treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-follow-up-after-initiation-of-therapy/abstract/29\" class=\"nounderline abstract_t\">Breen RA, Miller RF, Gorsuch T, et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis 2006; 193:1437.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8030 Version 19.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H29\"><span>SUMMARY</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2274974346\" id=\"outline-link-H2274974346\">INITIATION OF THERAPY</a></li><li><a href=\"#H1758484531\" id=\"outline-link-H1758484531\">DURATION OF THERAPY</a></li><li><a href=\"#H3288296675\" id=\"outline-link-H3288296675\">CLINICAL MONITORING</a><ul><li><a href=\"#H856245311\" id=\"outline-link-H856245311\">Sputum monitoring</a></li><li><a href=\"#H2848278702\" id=\"outline-link-H2848278702\">Drug-related side effects</a></li><li><a href=\"#H1868326374\" id=\"outline-link-H1868326374\">Therapeutic drug monitoring</a></li></ul></li><li><a href=\"#H7\" id=\"outline-link-H7\">PATIENTS WITH INADEQUATE CLINICAL RESPONSE</a><ul><li><a href=\"#H3793220151\" id=\"outline-link-H3793220151\">General principles</a></li><li><a href=\"#H2748843968\" id=\"outline-link-H2748843968\">Persistently positive sputum culture</a></li><li><a href=\"#H1971166980\" id=\"outline-link-H1971166980\">Persistent symptoms and/or radiographic findings</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">- Intercurrent opportunistic infection</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">- Immune reconstitution inflammatory syndrome</a></li></ul></li></ul></li><li><a href=\"#H25\" id=\"outline-link-H25\">OUTCOMES</a></li><li><a href=\"#H3454422568\" id=\"outline-link-H3454422568\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H29\" id=\"outline-link-H29\">SUMMARY</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/8030|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=ID/109259\" class=\"graphic graphic_algorithm\">- Rx drug-susceptible pulmonary TB in adults</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adherence-to-tuberculosis-treatment\" class=\"medical medical_review\">Adherence to tuberculosis treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=antituberculous-drugs-an-overview\" class=\"medical medical_review\">Antituberculous drugs: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-presentation-and-diagnosis-of-pneumocystis-pulmonary-infection-in-hiv-infected-patients\" class=\"medical medical_review\">Clinical presentation and diagnosis of Pneumocystis pulmonary infection in HIV-infected patients</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-of-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">Diagnosis of pulmonary tuberculosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=immune-reconstitution-inflammatory-syndrome\" class=\"medical medical_review\">Immune reconstitution inflammatory syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-opportunistic-infections-in-hiv-infected-adults-and-adolescents\" class=\"medical medical_society_guidelines\">Society guideline links: Opportunistic infections in HIV-infected adults and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-resistant-pulmonary-tuberculosis-in-adults\" class=\"medical medical_review\">Treatment of drug-resistant pulmonary tuberculosis in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-drug-susceptible-pulmonary-tuberculosis-in-hiv-uninfected-adults\" class=\"medical medical_review\">Treatment of drug-susceptible pulmonary tuberculosis in HIV-uninfected adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-pulmonary-tuberculosis-in-hiv-infected-adults-initiation-of-therapy\" class=\"medical medical_review\">Treatment of pulmonary tuberculosis in HIV-infected adults: Initiation of therapy</a></li></ul></div></div>","javascript":null}